247 related articles for article (PubMed ID: 24427314)
1. Gene and MicroRNA transcriptome analysis of Parkinson's related LRRK2 mouse models.
Dorval V; Mandemakers W; Jolivette F; Coudert L; Mazroui R; De Strooper B; Hébert SS
PLoS One; 2014; 9(1):e85510. PubMed ID: 24427314
[TBL] [Abstract][Full Text] [Related]
2. Homozygous mutation of the LRRK2 ROC domain as a novel genetic model of parkinsonism.
Chen ML; Wu RM
J Biomed Sci; 2022 Aug; 29(1):60. PubMed ID: 35965315
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein.
Cho HJ; Liu G; Jin SM; Parisiadou L; Xie C; Yu J; Sun L; Ma B; Ding J; Vancraenenbroeck R; Lobbestael E; Baekelandt V; Taymans JM; He P; Troncoso JC; Shen Y; Cai H
Hum Mol Genet; 2013 Feb; 22(3):608-20. PubMed ID: 23125283
[TBL] [Abstract][Full Text] [Related]
4. The parkinson's disease-associated LRRK2 mutation R1441G inhibits neuronal differentiation of neural stem cells.
Bahnassawy L; Nicklas S; Palm T; Menzl I; Birzele F; Gillardon F; Schwamborn JC
Stem Cells Dev; 2013 Sep; 22(18):2487-96. PubMed ID: 23600457
[TBL] [Abstract][Full Text] [Related]
5. Low-variance RNAs identify Parkinson's disease molecular signature in blood.
Chikina MD; Gerald CP; Li X; Ge Y; Pincas H; Nair VD; Wong AK; Krishnan A; Troyanskaya OG; Raymond D; Saunders-Pullman R; Bressman SB; Yue Z; Sealfon SC
Mov Disord; 2015 May; 30(6):813-21. PubMed ID: 25786808
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional responses to loss or gain of function of the leucine-rich repeat kinase 2 (LRRK2) gene uncover biological processes modulated by LRRK2 activity.
Nikonova EV; Xiong Y; Tanis KQ; Dawson VL; Vogel RL; Finney EM; Stone DJ; Reynolds IJ; Kern JT; Dawson TM
Hum Mol Genet; 2012 Jan; 21(1):163-74. PubMed ID: 21972245
[TBL] [Abstract][Full Text] [Related]
7. Identification of blood serum micro-RNAs associated with idiopathic and LRRK2 Parkinson's disease.
Botta-Orfila T; Morató X; Compta Y; Lozano JJ; Falgàs N; Valldeoriola F; Pont-Sunyer C; Vilas D; Mengual L; Fernández M; Molinuevo JL; Antonell A; Martí MJ; Fernández-Santiago R; Ezquerra M
J Neurosci Res; 2014 Aug; 92(8):1071-7. PubMed ID: 24648008
[TBL] [Abstract][Full Text] [Related]
8. Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression.
Gehrke S; Imai Y; Sokol N; Lu B
Nature; 2010 Jul; 466(7306):637-41. PubMed ID: 20671708
[TBL] [Abstract][Full Text] [Related]
9. Diapocynin prevents early Parkinson's disease symptoms in the leucine-rich repeat kinase 2 (LRRK2R¹⁴⁴¹G) transgenic mouse.
Dranka BP; Gifford A; Ghosh A; Zielonka J; Joseph J; Kanthasamy AG; Kalyanaraman B
Neurosci Lett; 2013 Aug; 549():57-62. PubMed ID: 23721786
[TBL] [Abstract][Full Text] [Related]
10. Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity.
Gillardon F; Schmid R; Draheim H
Neuroscience; 2012 Apr; 208():41-8. PubMed ID: 22342962
[TBL] [Abstract][Full Text] [Related]
11. A novel mitochondrially-targeted apocynin derivative prevents hyposmia and loss of motor function in the leucine-rich repeat kinase 2 (LRRK2(R1441G)) transgenic mouse model of Parkinson's disease.
Dranka BP; Gifford A; McAllister D; Zielonka J; Joseph J; O'Hara CL; Stucky CL; Kanthasamy AG; Kalyanaraman B
Neurosci Lett; 2014 Nov; 583():159-64. PubMed ID: 25263790
[TBL] [Abstract][Full Text] [Related]
12. An early axonopathy in a hLRRK2(R1441G) transgenic model of Parkinson disease.
Tagliaferro P; Kareva T; Oo TF; Yarygina O; Kholodilov N; Burke RE
Neurobiol Dis; 2015 Oct; 82():359-371. PubMed ID: 26192625
[TBL] [Abstract][Full Text] [Related]
13. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S.
Li X; Patel JC; Wang J; Avshalumov MV; Nicholson C; Buxbaum JD; Elder GA; Rice ME; Yue Z
J Neurosci; 2010 Feb; 30(5):1788-97. PubMed ID: 20130188
[TBL] [Abstract][Full Text] [Related]
14. Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation.
Matikainen-Ankney BA; Kezunovic N; Mesias RE; Tian Y; Williams FM; Huntley GW; Benson DL
J Neurosci; 2016 Jul; 36(27):7128-41. PubMed ID: 27383589
[TBL] [Abstract][Full Text] [Related]
15. Hypothesis: Do miRNAs Targeting the Leucine-Rich Repeat Kinase 2 Gene (LRRK2) Influence Parkinson's Disease Susceptibility?
Yılmaz ŞG; Geyik S; Neyal AM; Soko ND; Bozkurt H; Dandara C
OMICS; 2016 Apr; 20(4):224-8. PubMed ID: 27093107
[TBL] [Abstract][Full Text] [Related]
16. Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression.
Henry AG; Aghamohammadzadeh S; Samaroo H; Chen Y; Mou K; Needle E; Hirst WD
Hum Mol Genet; 2015 Nov; 24(21):6013-28. PubMed ID: 26251043
[TBL] [Abstract][Full Text] [Related]
17. Cognitive and behavioral symptoms in Parkinson's disease patients with the G2019S and R1441G mutations of the LRRK2 gene.
Somme JH; Molano Salazar A; Gonzalez A; Tijero B; Berganzo K; Lezcano E; Fernandez Martinez M; Zarranz JJ; Gómez-Esteban JC
Parkinsonism Relat Disord; 2015 May; 21(5):494-9. PubMed ID: 25840672
[TBL] [Abstract][Full Text] [Related]
18. Non-motor and motor features in LRRK2 transgenic mice.
Bichler Z; Lim HC; Zeng L; Tan EK
PLoS One; 2013; 8(7):e70249. PubMed ID: 23936174
[TBL] [Abstract][Full Text] [Related]
19. The mouse/human cross-species heterodimer of leucine-rich repeat kinase 2: possible significance in the transgenic model mouse of Parkinson's disease.
Miyajima T; Ohta E; Kawada H; Maekawa T; Obata F
Neurosci Lett; 2015 Feb; 588():142-6. PubMed ID: 25562633
[TBL] [Abstract][Full Text] [Related]
20. Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease.
Li X; Wang QJ; Pan N; Lee S; Zhao Y; Chait BT; Yue Z
PLoS One; 2011 Mar; 6(3):e17153. PubMed ID: 21390248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
